/Dr. Harsh Vardhan launches the country’s first pneumococcal conjugate vaccine

Dr. Harsh Vardhan launches the country’s first pneumococcal conjugate vaccine

India’s first pneumococcal conjugate vaccine (PCV) was launched today by Union Health and Family Welfare Minister Dr Harsh Vardhan. The vaccine “Pneumosil” was developed by the Serum Institute of India Pvt Ltd (SIIPL) in partnership with Bill and the Melinda Gates Foundation.

Recognizing SIIPLas as the world’s largest vaccine maker and its contribution to the Indian economy, Dr. Harsh Vardhan commented that the Serum Institute’s vaccines are used in 170 countries and that every third child in the world is immunized by the manufacturer’s vaccine. He reminded the audience that SIIPL had developed and licensed the first indigenous pneumococcal conjugate vaccine (PCV) from the Government of India during the COVID-19 Pandemic Lock-Downin Line with Prime Minister Shito. Narendra Modi ji’s focus is on ‘Atmanirbhar Bharat’. He also referred to the extraordinary efforts made by the Ministry of Health and Family Welfare in this endeavor to manufacture Indiaself-Reliantin PCV.
Describing SIIPL’s achievements in tailoring vaccine tailoring to India, Dr. Harsh Vardhan said, “The Serum Institute’s first indigenous pneumococcal conjugate vaccine is marketed under the brand name” Pneumosil “in single doses (violin and pre-filled syringe) and multidos. The pneumococcal has been extensively evaluated in 5 randomized controlled clinical trials and demonstrated comparable safety and immunity against licensed pneumococcal vaccines in various populations in India and Africa, where adults, infants, and pneumococci were given. Babies use different vaccination schedules. SEC), ”he added.

Describing SIIPL’s achievements in tailoring vaccine tailoring to India, Dr. Harsh Vardhan said, “The Serum Institute’s first indigenous pneumococcal conjugate vaccine is marketed under the brand name” Pneumosil “in single doses (violin and pre-filled syringe) and multidos. The pneumococcal has been extensively evaluated in 5 randomized controlled clinical trials and demonstrated comparable safety and immunity against licensed pneumococcal vaccines in various populations in India and Africa, where adults, infants, and pneumococci were given. Babies use different vaccination schedules. SEC), ”he added.

Talking about the Prime Minister’s commitment to Atmanirbhar India and his vision of ‘Making in India for the World’, Dr. Harsh Vardhan said, “Pneumosil Research and Development & High End is an example of India’s potential in the manufacture of vaccines. In fact, our country is proud of this historic milestone during the COVID-19 epidemic, because so far we have relied entirely on pneumococcal conjugate vaccine manufactured by foreign manufacturers, which are available at very high prices. He took the occasion to remind audiences that pneumonia is the single biggest epidemic of death among children under the age of five worldwide, with nearly 10 million deaths worldwide.
Appreciating the scientific and medical brotherhood of the country, he said, “I am sure that the Serum Institute of India and others in the entire scientific and medical community will continue their efforts to develop more life-saving vaccines in the future.”

The event was attended by Additional Secretary (MOFFW) Dr Manohar Agni and other senior officials of the ministry.

Dr. Cyrus Poonavalla, Chairman, Poonavalla Group of Industries, and Shri Adar Poonavalla, Chief Executive Officer, Serum Institute of India Pvt. Ltd. (SIIPL), SIIPL.

Share This